Tim Lugo

Stock Analyst at William Blair

(0.45)
# 4,018
Out of 4,884 analysts
23
Total ratings
33.33%
Success rate
-28.45%
Average return

Stocks Rated by Tim Lugo

BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $57.50
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.32
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $32.53
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $5.03
Upside: +695.23%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.74
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $189.28
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.44
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $15.01
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $16.52
Upside: -
Vistagen Therapeutics
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.00
Upside: -
Downgrades: Market Perform
Price Target: $62
Current: $9.20
Upside: +573.91%
Initiates: Outperform
Price Target: n/a
Current: $3.74
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $33.26
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $1.17
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $0.34
Upside: -
Initiates: Outperform
Price Target: $46
Current: $14.63
Upside: +214.42%